Trinity Biotech (TRIB) Cash & Equivalents (2009 - 2025)

Trinity Biotech (TRIB) has reported Cash & Equivalents for 17 consecutive years, with $5.1 million the latest figure, recorded in Q4 2025.

• Quarterly Cash & Equivalents fell 0.56% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 0.56% YoY) and the FY2025 annual result came in at $5.1 million, down 0.56% from the prior year.
• Cash & Equivalents fell to $5.1 million in Q4 2025 per TRIB's latest filing, from $5.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TRIB reached as high as $32.3 million in Q1 2021 and fell as low as $2.8 million in Q3 2024.
• A 5-year average of $13.8 million and a median of $8.3 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 143.71% — and 2024, when it plunged 80.04%.
• Year by year, Cash & Equivalents stood at $25.9 million in 2021, then slumped by 74.61% to $6.6 million in 2022, then plunged by 43.89% to $3.7 million in 2023, then surged by 39.99% to $5.2 million in 2024, then dropped by 0.56% to $5.1 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $5.1 million, $5.2 million, and $5.2 million for Q4 2025, Q2 2025, and Q4 2024 respectively.